United Therapeutics (UTHR)


Market Price (11/19/2026): $577.29 | Market Cap: $24.6 BilSector: Health Care | Industry: Biotechnology

United Therapeutics (UTHR)


Market Price (11/19/2026): $577.29
Market Cap: $24.6 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 39%

Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 45%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 27%

Stock buyback support
Stock Buyback 3Y Total is 4.1 Bil

Low stock price volatility
Vol 12M is 35%

Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more.

Key risks
UTHR key risks include [1] patent expirations on its core products, Show more.

0 Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 39%
1 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 45%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 27%
2 Stock buyback support
Stock Buyback 3Y Total is 4.1 Bil
3 Low stock price volatility
Vol 12M is 35%
4 Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more.
5 Key risks
UTHR key risks include [1] patent expirations on its core products, Show more.

UTHR in ETFs

Weight = UTHR's share of each fund

VTI0.04%
ITOT0.03%
IWB0.03%
IJH0.74%
VB0.32%
QVAL2.3%
XBI1.8%
IBB1.7%
+26 more covered ETFs

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Prices as of 11/18/2026

Nov 5: down 7.0% in one day (S&P 500 down 4.4%)
The market widely fell, driven by growing concerns about AI, as indicated by various market headlines. This broad market downturn led the company's stock to decline significantly.

Up 28.9% from its Sep 24 low to Nov 4, down 5.1% since (S&P 500 down 0.0%)
The stock gained on news of a favorable patent ruling against a competitor and a new share repurchase authorization. The ruling was announced on September 30, and the share repurchase authorization on October 22.

Nov 4: up 1.2% on its earnings report (S&P 500 up 1.7%)
The stock rose slightly as the company reported its Fiscal Third Quarter 2026 financial results and announced a royalty buydown. The broader market was broadly positive, which helped drive the stock's gain.

Show more
Prices as of 11/18/2026

Nov 5: down 7.0% in one day (S&P 500 down 4.4%)
The market widely fell, driven by growing concerns about AI, as indicated by various market headlines. This broad market downturn led the company's stock to decline significantly.

Up 28.9% from its Sep 24 low to Nov 4, down 5.1% since (S&P 500 down 0.0%)
The stock gained on news of a favorable patent ruling against a competitor and a new share repurchase authorization. The ruling was announced on September 30, and the share repurchase authorization on October 22.

Nov 4: up 1.2% on its earnings report (S&P 500 up 1.7%)
The stock rose slightly as the company reported its Fiscal Third Quarter 2026 financial results and announced a royalty buydown. The broader market was broadly positive, which helped drive the stock's gain.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The 11.5% change in UTHR stock from 7/31/2026 to 11/18/2026 was primarily driven by a 14.5% change in the company's P/E Multiple.
(LTM values as of)731202611182026Change
Stock Price ($)517.71577.3411.5%
Change Contribution By: 
Total Revenues ($ Mil)3,1703,1880.6%
Net Income Margin (%)40.6%38.6%-4.9%
P/E Multiple17.520.014.5%
Shares Outstanding (Mil)44431.9%
Cumulative Contribution11.5%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/18/2026
ReturnCorrelation
UTHR11.5% 
Market (SPY)-2.0%22.3%
Sector (XLV)11.9%12.7%

Fundamental Drivers

The 1.0% change in UTHR stock from 4/30/2026 to 11/18/2026 was primarily driven by a 7.8% change in the company's P/E Multiple.
(LTM values as of)430202611182026Change
Stock Price ($)571.35577.341.0%
Change Contribution By: 
Total Revenues ($ Mil)3,1833,1880.2%
Net Income Margin (%)41.9%38.6%-7.9%
P/E Multiple18.620.07.8%
Shares Outstanding (Mil)43431.6%
Cumulative Contribution1.0%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/18/2026
ReturnCorrelation
UTHR1.0% 
Market (SPY)2.1%13.7%
Sector (XLV)25.1%18.5%

Fundamental Drivers

The 29.6% change in UTHR stock from 10/31/2025 to 11/18/2026 was primarily driven by a 30.6% change in the company's P/E Multiple.
(LTM values as of)1031202511182026Change
Stock Price ($)445.43577.3429.6%
Change Contribution By: 
Total Revenues ($ Mil)3,1283,1881.9%
Net Income Margin (%)40.7%38.6%-5.0%
P/E Multiple15.320.030.6%
Shares Outstanding (Mil)44432.6%
Cumulative Contribution29.6%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 11/18/2026
ReturnCorrelation
UTHR29.6% 
Market (SPY)8.2%16.3%
Sector (XLV)27.7%23.8%

Fundamental Drivers

The 159.1% change in UTHR stock from 10/31/2023 to 11/18/2026 was primarily driven by a 67.0% change in the company's P/E Multiple.
(LTM values as of)1031202311182026Change
Stock Price ($)222.86577.34159.1%
Change Contribution By: 
Total Revenues ($ Mil)2,1113,18851.0%
Net Income Margin (%)41.3%38.6%-6.5%
P/E Multiple12.020.067.0%
Shares Outstanding (Mil)47439.8%
Cumulative Contribution159.1%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2023 to 11/18/2026
ReturnCorrelation
UTHR159.1% 
Market (SPY)81.1%16.5%
Sector (XLV)52.9%25.5%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
UTHR Return42%29%-21%60%38%18%280%
Peers Return35%20%8%1%58%38%282%
S&P 500 Return27%-19%24%23%16%8%97%

Monthly Win Rates [3]
UTHR Win Rate67%42%42%58%50%36% 
Peers Win Rate60%53%40%48%62%64% 
S&P 500 Win Rate75%42%67%75%67%36% 

Max Drawdowns [4]
UTHR Max Drawdown-20%-23%-26%-14%-28%-21% 
Peers Max Drawdown-19%-25%-27%-27%-23%-26% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: JNJ, MRK, PFE, GILD, LQDA. See UTHR Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/18/2026 (YTD)

How Low Can It Go

EventUTHRS&P 500
2025 US Tariff Shock
  % Loss-27.4%-18.8%
  % Gain to Breakeven37.7%23.1%
  Time to Breakeven83 days79 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-11.1%-9.5%
  % Gain to Breakeven12.5%10.5%
  Time to Breakeven84 days24 days
2023 SVB Regional Banking Crisis
  % Loss-19.8%-6.7%
  % Gain to Breakeven24.8%7.1%
  Time to Breakeven197 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-21.1%-24.5%
  % Gain to Breakeven26.8%32.4%
  Time to Breakeven84 days427 days
2020 COVID-19 Crash
  % Loss-25.7%-33.7%
  % Gain to Breakeven34.7%50.9%
  Time to Breakeven35 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-21.2%-19.2%
  % Gain to Breakeven27.0%23.8%
  Time to Breakeven674 days105 days

Compare to JNJ, MRK, PFE, GILD, LQDA

In The Past

United Therapeutics's stock fell -27.4% during the 2025 US Tariff Shock. Such a loss loss requires a 37.7% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventUTHRS&P 500
2025 US Tariff Shock
  % Loss-27.4%-18.8%
  % Gain to Breakeven37.7%23.1%
  Time to Breakeven83 days79 days
2022 Inflation Shock & Fed Tightening
  % Loss-21.1%-24.5%
  % Gain to Breakeven26.8%32.4%
  Time to Breakeven84 days427 days
2020 COVID-19 Crash
  % Loss-25.7%-33.7%
  % Gain to Breakeven34.7%50.9%
  Time to Breakeven35 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-21.2%-19.2%
  % Gain to Breakeven27.0%23.8%
  Time to Breakeven674 days105 days
2015-2016 China Devaluation / Global Growth Scare
  % Loss-31.3%-12.2%
  % Gain to Breakeven45.6%13.9%
  Time to Breakeven1803 days62 days
2011 US Debt Ceiling Crisis & European Contagion
  % Loss-34.4%-17.9%
  % Gain to Breakeven52.3%21.8%
  Time to Breakeven317 days123 days
2008-2009 Global Financial Crisis
  % Loss-51.3%-53.4%
  % Gain to Breakeven105.3%114.4%
  Time to Breakeven307 days1085 days

Compare to JNJ, MRK, PFE, GILD, LQDA

In The Past

United Therapeutics's stock fell -27.4% during the 2025 US Tariff Shock. Such a loss loss requires a 37.7% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About United Therapeutics (UTHR)

United Therapeutics Corporation (UTHR) is a biotechnology company dedicated to developing and commercializing innovative therapies for patients suffering from chronic and life-threatening diseases. The company's primary focus is on pulmonary hypertension (PH), including pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), a group of severe conditions affecting the heart and lungs.

Its main commercial products are designed to improve symptoms and exercise capacity in PAH patients. These include Remodulin (an injectable prostacyclin analogue), Tyvaso (an inhaled formulation of treprostinil), Orenitram (an oral treprostinil tablet), and Adcirca (an oral PDE-5 inhibitor). United Therapeutics also offers Unituxin, a monoclonal antibody for treating high-risk neuroblastoma. These therapies address significant unmet medical needs in specialized markets.

The company maintains a robust development pipeline, actively working on new formulations and delivery systems for its existing compounds, such as Tyvaso DPI (a dry powder inhaler) and the Remunity Pump for subcutaneous treprostinil delivery. Furthermore, UTHR is exploring advanced therapies like Aurora-GT, a gene therapy aimed at rebuilding lung blood vessels, and Ralinepag for PAH. United Therapeutics serves patients globally, with a continuous commitment to expanding treatment options for severe and rare diseases.

AI Analysis | Feedback

  • Vertex Pharmaceuticals for pulmonary hypertension.
  • An early Gilead Sciences, but for complex lung diseases like pulmonary hypertension.

AI Analysis | Feedback

```html
  • Remodulin: An injectable therapy used to treat pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise.
  • Tyvaso: An inhaled formulation of treprostinil that enhances exercise ability in patients with PAH and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
  • Orenitram: An oral tablet dosage form of treprostinil designed to enhance exercise capacity in PAH patients.
  • Unituxin: A monoclonal antibody approved for treating high-risk neuroblastoma.
  • Adcirca: An oral PDE-5 inhibitor prescribed to enhance exercise ability in patients with PAH.
  • Tyvaso DPI: A dry powder inhalation form of Tyvaso currently under development.
  • Remunity Pump: A small, lightweight, and durable pump system being developed for the subcutaneous delivery of treprostinil.
  • RemoPro: A developing treatment targeting pulmonary arterial hypertension (PAH).
  • Ralinepag: A developing oral investigational drug for the treatment of pulmonary arterial hypertension (PAH).
  • Aurora-GT: A gene therapy product in development aimed at rebuilding blood vessels in the lungs.
```

AI Analysis | Feedback

United Therapeutics (UTHR) sells primarily to individuals, specifically patients suffering from chronic and life-threatening diseases. While their products are distributed through healthcare channels such as hospitals, pharmacies, and specialty distributors, the ultimate beneficiaries and categories of customers they serve are patients.

The major categories of patients served by United Therapeutics are:

  • Patients with Pulmonary Arterial Hypertension (PAH): This is a primary focus area, with multiple therapies (Remodulin, Tyvaso, Orenitram, Adcirca, RemoPro, Ralinepag) developed for this condition.
  • Patients with other forms of Pulmonary Hypertension: This includes patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and those with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), for whom Tyvaso is either approved or under study.
  • Patients with high-risk neuroblastoma: Unituxin is a specific therapy developed to treat this type of cancer.

AI Analysis | Feedback

DEKA Research & Development Corp.

MannKind Corporation (MNKD)

Arena Pharmaceuticals, Inc.

AI Analysis | Feedback

Martine Rothblatt, Founder, Chairperson, and Chief Executive Officer

Dr. Martine Rothblatt founded United Therapeutics in 1996 and has served as Chairperson and Chief Executive Officer since its inception. She was motivated to enter biotech after her daughter was diagnosed with pulmonary arterial hypertension. Previously, she created the satellite radio company SiriusXM (co-founded in 1990), serving as its Chairman and CEO. Rothblatt also served as President and CEO of GeoStar, a satellite navigation company, after graduating with law and MBA degrees from UCLA. She left Sirius in 1992 and WorldSpace (another company she created) in 1997 to become full-time Chairman and CEO of United Therapeutics. Forbes recognized Rothblatt in their "50 Over 50" and "America's Self-Made Women" lists in 2023.

James Edgemond, Chief Financial Officer and Treasurer

Mr. James Edgemond was promoted to Chief Financial Officer and Treasurer of United Therapeutics in March 2015. He joined the company in January 2013 as Treasurer and Vice President, Strategic Financial Planning. Before joining United Therapeutics, he was Vice President, Corporate Controller, and Treasurer of Clark Construction Group from 2008 through January 2013. He also held various roles at The Corporate Executive Board Company from 1998 to 2008, including Executive Director, Finance. Mr. Edgemond began his career in public accounting at KPMG Peat Marwick LLP, serving in various roles, including Senior Manager, from 1990 to 1998.

Michael Benkowitz, President and Chief Operating Officer

Mr. Michael Benkowitz joined United Therapeutics in 2011 as Executive Vice President, Organizational Development, and was promoted to President and Chief Operating Officer in 2016. In his current role, he is responsible for all commercial, medical affairs, and corporate compliance activities, most company-wide administrative functions (including human resources and information technology), many business development efforts, and several key business alliances and partnerships. Prior to United Therapeutics, his career included work as a consultant.

Paul A. Mahon, J.D., Executive Vice President, General Counsel, and Corporate Secretary

Paul A. Mahon serves as the Executive Vice President, General Counsel, and Corporate Secretary for United Therapeutics. He is a key member of the leadership team.

AI Analysis | Feedback

The key risks to United Therapeutics' business are its significant reliance on treprostinil-based therapies, the inherent risks associated with its pipeline development and regulatory approvals, and intense competition within the pulmonary arterial hypertension (PAH) market.

  1. Reliance on Treprostinil-based Therapies and Generic Competition/Patent Expiration: United Therapeutics is heavily dependent on its treprostinil-based therapies, such as the Tyvaso franchise, which accounts for approximately 60% of the company's total revenue. The company faces significant threats from generic competition as patents on key products, including Remodulin and Tyvaso, expire. This generic competition can lead to price erosion and reduced market share, thereby weakening the company's competitive advantage. The company is also involved in litigation concerning generic competition and patent rights related to its treprostinil-based products.
  2. Pipeline Development and Regulatory Risks: A significant portion of United Therapeutics' future growth hinges on the successful development and regulatory approval of its pipeline products, such as Tyvaso DPI, Remunity Pump, RemoPro, Ralinepag, Aurora-GT, and new indications for Tyvaso. Any setbacks in clinical trials, delays in regulatory timelines for products like Ralinepag, or challenges with the xenotransplantation pipeline could significantly impact the company's future revenue and growth prospects. Furthermore, expanding into complex areas like organ manufacturing technologies presents operational risks due to untested processes.
  3. Intense Competition in the PAH Market: United Therapeutics operates in a highly competitive PAH treatment landscape, with numerous branded and generic drugs already on the market. New entrants, such as Winrevair and Yutrepia, are actively vying for market share, contributing to rising competitive pressures. This competitive environment, including various approved PAH therapies like oral ERAs, prostacyclin-class therapies, and PDE-5 inhibitors, poses a constant threat to United Therapeutics' market position and revenues.

AI Analysis | Feedback

null

AI Analysis | Feedback

United Therapeutics Corporation (UTHR) operates in the biotechnology sector, focusing on therapies for chronic and life-threatening diseases, including pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH-ILD), and neuroblastoma. The addressable markets for its main products are substantial, spanning both global and U.S. regions.

Pulmonary Arterial Hypertension (PAH) Market

United Therapeutics' products such as Remodulin, Tyvaso, Orenitram, and Adcirca address the Pulmonary Arterial Hypertension (PAH) market.

  • The global PAH market was valued at approximately USD 8.3 billion in 2024 and is projected to grow to about USD 13.9 billion by 2034.
  • In the U.S., the PAH market was valued at approximately USD 4 billion in 2024.

Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) Market

Tyvaso (including Tyvaso DPI) is approved for Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD).

  • The total market size for PH-ILD across the 7 Major Markets (7MM), which include the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, was approximately USD 3 billion in 2024.
  • Specifically, the PH-ILD market in the U.S. was valued at approximately USD 2 billion in 2024.

Neuroblastoma Treatment Market

Unituxin is a monoclonal antibody for treating high-risk neuroblastoma.

  • The global neuroblastoma treatment market was estimated at around USD 1.2 billion in 2024, with projections to reach approximately USD 2.1 billion by 2030.
  • North America is a leading region in the neuroblastoma market, holding over a 40% share in 2024.

Idiopathic Pulmonary Fibrosis (IPF) Market (Potential for Tyvaso)

United Therapeutics is developing Tyvaso for Idiopathic Pulmonary Fibrosis (IPF), with positive phase III results reported.

  • The U.S. IPF market is estimated to comprise more than 100,000 patients and could represent a market opportunity of over USD 4 billion if Tyvaso is approved for this indication.

AI Analysis | Feedback

United Therapeutics Corporation (UTHR) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and product advancements:

  1. Continued Growth of Tyvaso and Tyvaso DPI: The company anticipates sustained double-digit revenue growth from its Tyvaso franchise, particularly Tyvaso DPI (dry powder inhaler). This growth is attributed to increasing patient adoption in both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) markets, as well as the introduction of higher-dose cartridges for enhanced patient convenience.
  2. Launch of New Inhaled Treprostinil Products: United Therapeutics plans to file for regulatory approval of Tresmi, a soft mist inhaler, and a "super prostacyclin" in 2026, with commercial launches targeted for 2027. Tresmi aims to address and significantly reduce cough, a common side effect of dry powder inhalers. The "super prostacyclin" is designed to usher in a new era of once-a-day treatments for pulmonary hypertension.
  3. Commercialization of Ralinepag: The positive results from the ADVANCE OUTCOMES study for ralinepag, an investigational once-daily oral dosing therapy, are expected to significantly contribute to the company's PAH franchise. Analysts believe these results support approval, with ralinepag offering a projected patent life through approximately 2040 and the potential for once-daily dosing.
  4. Introduction of a New Idiopathic Pulmonary Fibrosis (IPF) Treatment: Building on the "unprecedented treatment benefit" observed in the TETON-2 study for idiopathic pulmonary fibrosis, United Therapeutics is optimistic about similar positive outcomes from its TETON-1 study. The company expects to launch a new IPF treatment by June 2027, positioning it as a major long-term revenue driver.
  5. Expansion through RemunityPRO Pump: The recent launch of the RemunityPRO pump for subcutaneous delivery of Remodulin is expected to support revenue growth. This new device offers automated priming and lower flow rates, facilitating at-home initiation of Remodulin therapy.

AI Analysis | Feedback

Share Repurchases

  • In March 2026, United Therapeutics' Board of Directors authorized a new stock repurchase program of up to $2 billion over the next year, with an initial $1.5 billion Accelerated Share Repurchase (ASR) program executed with Citibank.
  • In March 2024, the company's Board authorized a $1 billion share repurchase program, entering into a $1 billion Accelerated Share Repurchase (ASR) agreement with Citibank.
  • In July/August 2025, a $1 billion repurchase program was authorized and subsequently implemented through Accelerated Share Repurchase agreements with Citi.

Share Issuance

  • United Therapeutics' shares outstanding increased by 2.47% in 2023, reaching 0.05 billion.
  • Shares outstanding subsequently decreased by 2.41% in 2024 to 0.049 billion.
  • In 2025, shares outstanding further declined by 1.24% to 0.048 billion.

Outbound Investments

  • In October 2023, United Therapeutics acquired Miromatrix, a company developing biologic human organs for transplantation, for $91 million.
  • Over the last five years (2020-2025), the company has made an average of 0.4 acquisitions per year.

Capital Expenditures

  • Capital expenditures were $230 million in 2023 and $247 million in 2024.
  • Expected capital expenditures are $246.5 million for 2025 and $120 million for 2026.
  • Significant capital investments have been directed towards supporting a new Tyvaso DPI manufacturing facility in North Carolina and acquiring additional real estate for future commercial manufacturing needs.

Better Bets vs. United Therapeutics (UTHR)

Peer Outperformance in Biotechnology

UTHR has outperformed 92% of its 369 Biotechnology peers over 5Y. Among the peers that beat it are ROIV and EXEL. Biotechnology ranks 9th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Biotechnology constituents that UTHR has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
78%
of 452 industry peers · 21.1% return
3Y
85%
of 399 industry peers · 152.2% return
5Y
92%
of 369 industry peers · 185.0% return
Biotechnology peers with revenue growth within 4pp of UTHR's that beat it on at least 2 of 3 windows, and by at least 20pp over 5Y. Growth is matched by construction, so the gap is largely a re-rating gap. The multiple column is the context for it.
Ticker Name Rev Growth 3Y Avg P/E 1Y3Y5Y 5Y Gap
UTHR United Therapeutics 13.5% 20.0x 21.1%152.2%185.0% —
ROIV Roivant Sciences 16.6% -81.3x 88.7%331.8%377.0% +192pp
EXEL Exelixis 12.1% 19.0x 60.1%223.2%290.5% +106pp
Price returns, excluding dividends. P/E shown for context only and not used for matching.
Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is UTHR's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Health Care Distributors 5 20.4%83.0%196.8% CAH 525% · MCK 393% · COR 197%
Health Care Services 20 30.3%21.9%13.8% RDNT 157% · HIMS 130% · DGX 93%
Health Care Facilities 26 12.5%14.3%-7.7% THC 245% · NHC 223% · EHC 185%
Managed Health Care 8 56.6%-8.0%-9.8% OSCR 159% · HQY 55% · ELV 1%
Health Care Equipment 49 -0.4%5.4%-17.6% GKOS 394% · UFPT 358% · TMDX 319%
Health Care Supplies 11 24.2%1.3%-40.0% LNTH 252% · HAE 120% · MMSI 26%
Pharmaceuticals 60 -16.4%3.2%-41.7% LQDA 1121% · KNSA 653% · XERS 611%
Life Sciences Tools & Services 110 -19.2%-24.9%-75.1% AXGN 462% · MEDP 186% · NTRA 176%
Biotechnology ← 370 -33.9%-40.4%-84.4% ELVN 1240% · TRVI 1212% · DNTH 1117%
Health Care Technology 23 -20.6%-60.0%-86.6% VEEV -10% · DOCS -53%
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.

Latest Trefis Analyses

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

UTHRJNJMRKPFEGILDLQDAMedian
NameUnited T.Johnson .Merck Pfizer Gilead S.Liquidia  
Mkt Price577.29272.53137.4628.02169.5256.46153.49
Mkt Cap24.7656.7339.3159.7210.55.1185.1
Rev LTM3,18899,33567,37863,62430,98762247,306
Op Inc LTM1,25525,5256,20116,62411,6992938,950
FCF LTM86219,59514,74611,78613,78028812,783
FCF 3Y Avg96119,10014,21210,13010,7912910,460
CFO LTM1,43026,15918,70314,17314,47932414,326
CFO 3Y Avg1,37425,17018,01112,83811,3894512,114

Growth & Margins

UTHRJNJMRKPFEGILDLQDAMedian
NameUnited T.Johnson .Merck Pfizer Gilead S.Liquidia  
Rev Chg LTM1.9%7.8%4.9%1.3%6.5%798.4%5.7%
Rev Chg 3Y Avg13.5%5.9%4.4%-2.9%4.2%375.7%5.1%
Rev Chg Q4.1%5.9%4.7%-0.4%6.8%314.6%5.3%
QoQ Delta Rev Chg LTM1.0%1.4%1.2%-0.1%1.7%37.9%1.3%
Op Inc Chg LTM-17.5%7.9%-72.3%-1.7%4.1%373.2%1.2%
Op Inc Chg 3Y Avg6.0%4.4%19.8%16.3%0.0%89.4%11.1%
Op Mgn LTM39.4%25.7%9.2%26.1%37.8%47.1%31.9%
Op Mgn 3Y Avg45.6%25.4%22.2%23.3%37.4%-274.3%24.4%
QoQ Delta Op Mgn LTM-5.1%-1.1%-1.3%-0.6%-0.7%9.7%-0.9%
CFO/Rev LTM44.9%26.3%27.8%22.3%46.7%52.1%36.3%
CFO/Rev 3Y Avg45.3%27.1%27.7%20.6%38.5%-220.3%27.4%
FCF/Rev LTM27.0%19.7%21.9%18.5%44.5%46.3%24.5%
FCF/Rev 3Y Avg31.8%20.6%21.9%16.2%36.4%-233.9%21.2%

Valuation

UTHRJNJMRKPFEGILDLQDAMedian
NameUnited T.Johnson .Merck Pfizer Gilead S.Liquidia  
Mkt Cap24.7656.7339.3159.7210.55.1185.1
P/S7.76.65.02.56.88.16.7
P/Op Inc19.625.754.79.618.017.218.8
P/EBIT16.235.150.522.9-138.3-58.919.6
P/E20.040.8138.339.6-54.5-53.729.8
P/CFO17.225.118.111.314.515.616.4
Total Yield5.0%4.4%3.2%8.6%0.1%-1.9%3.8%
Dividend Yield0.0%1.9%2.5%6.1%2.0%0.0%1.9%
FCF Yield 3Y Avg5.2%4.0%5.2%6.5%7.7%-2.2%5.2%
D/E0.00.10.20.40.10.00.1
Net D/E-0.10.00.10.30.1-0.00.1

Returns

UTHRJNJMRKPFEGILDLQDAMedian
NameUnited T.Johnson .Merck Pfizer Gilead S.Liquidia  
1M Rtn6.3%7.4%-4.3%-3.4%10.7%65.4%6.8%
3M Rtn9.1%0.2%-9.2%0.7%15.5%-25.0%0.4%
6M Rtn2.4%20.1%23.2%12.2%31.3%-8.6%16.1%
12M Rtn21.1%39.3%46.7%17.5%36.6%87.0%38.0%
3Y Rtn152.2%98.1%48.0%13.7%147.0%791.9%122.5%
1M Excs Rtn8.1%8.9%-3.5%-1.8%12.2%59.2%8.5%
3M Excs Rtn13.7%5.4%-4.3%5.2%21.8%-17.6%5.3%
6M Excs Rtn2.6%20.3%23.5%12.4%31.5%-8.4%16.4%
12M Excs Rtn11.2%28.5%41.2%8.1%28.8%87.6%28.6%
3Y Excs Rtn88.1%33.0%-21.0%-50.6%80.3%724.5%56.6%

FDA Approved Drugs Data

Expand for More
Post-Approval Fwd Returns
FDA
App #
Brand
Name
Generic
Name
Dosage
Form
FDA
Approval
3M
Rtn
6M
Rtn
1Y
Rtn
2Y
Rtn
Total
Rtn
NDA214324  TYVASO DPItreprostinilpowder52320224.8%26.4%2.9%31.6%174.7%
NDA208276  REMODULINtreprostinilsolution7302018-2.2%-3.3%-33.9%-6.3%380.1%
BLA125516  UNITUXINdinutuximabinjectable31020158.7%-5.9%-24.3%-10.6%252.4%
NDA203496  ORENITRAMtreprostinil diolaminetablet, extended release122020137.9%-0.4%52.0%76.7%557.3%
NDA022387  TYVASOtreprostinilsolution730200936.2%85.4%53.4%80.1%1,711.9%
Collapse to Preview
Post-Approval Fwd Returns
FDA
App #
Brand
Name
Generic
Name
Dosage
Form
FDA
Approval
3M
Rtn
6M
Rtn
1Y
Rtn
2Y
Rtn
Total
Rtn
NDA214324  TYVASO DPItreprostinilpowder52320224.8%26.4%2.9%31.6%174.7%
NDA208276  REMODULINtreprostinilsolution7302018-2.2%-3.3%-33.9%-6.3%380.1%
BLA125516  UNITUXINdinutuximabinjectable31020158.7%-5.9%-24.3%-10.6%252.4%
NDA203496  ORENITRAMtreprostinil diolaminetablet, extended release122020137.9%-0.4%52.0%76.7%557.3%
NDA022387  TYVASOtreprostinilsolution730200936.2%85.4%53.4%80.1%1,711.9%

Clinical Pipeline

Drug CandidateIndicationPhase 3 TrialsEst. Primary Completion
RalinepagPulmonary Arterial Hypertension1Dec 2026
Inhaled TreprostinilProgressive Pulmonary Fibrosis2Nov 2027
Active Phase 3 studies led by the company. Source: ClinicalTrials.gov · Updated 8/28/2026

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Tyvaso DPI1,2921,0347311580
Nebulized Tyvaso586587503715608
Remodulin527538495500514
Orenitram497434359325306
Unituxin227239199183202
Adcirca3024294156
Other242212140
Total3,1832,8772,3281,9361,686


Operating Income by Segment
$ Mil2005
Pharmaceutical66
Telemedicine-1
Total65


Assets by Segment
$ Mil20102009200820072006
PHARMACEUTICAL1,4091,031   
TELEMEDICINE2320   
Pharmaceutical  854555466
Telemedicine  183212
Total1,4321,052871587479


Price Behavior

Price Behavior
Market Price$577.34 
Market Cap ($ Bil)24.7 
First Trading Date06/17/1999 
Distance from 52W High-5.1% 
   50 Days200 Days
DMA Price$547.74$539.09
DMA Trendupup
Distance from DMA5.4%7.1%
 3M1YR
Volatility40.2%35.0%
Downside Capture-8.2911.98
Upside Capture54.2235.88
Correlation (S&P 500)24.1%16.1%
UTHR Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta-0.15-0.47-0.30-0.150.210.36
Up Beta-8.27-2.24-0.950.110.450.38
Down Beta-0.84-0.15-0.46-0.130.120.50
Up Capture148%24%25%-12%24%17%
Bmk +ve Days12182862130427
Stock +ve Days14223158124394
Down Capture-21%-115%-66%-39%-2%24%
Bmk -ve Days10253664121325
Stock -ve Days8213368127357

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with UTHR
UTHR22.4%35.0%0.62-
Sector ETF (XLV)21.5%17.0%0.9623.7%
Equity (SPY)10.9%13.8%0.4916.8%
Gold (GLD)-8.2%29.0%-0.302.3%
Commodities (DBC)28.8%21.5%1.07-5.8%
Real Estate (VNQ)11.2%14.2%0.5013.6%
Bitcoin (BTCUSD)-29.6%43.7%-0.6913.6%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with UTHR
UTHR23.3%35.1%0.66-
Sector ETF (XLV)8.0%15.4%0.3329.9%
Equity (SPY)11.0%17.3%0.4620.1%
Gold (GLD)14.5%19.2%0.605.6%
Commodities (DBC)6.8%19.6%0.245.8%
Real Estate (VNQ)1.1%19.0%-0.0517.5%
Bitcoin (BTCUSD)-0.0%51.4%0.189.7%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with UTHR
UTHR16.9%35.1%0.53-
Sector ETF (XLV)12.1%16.8%0.5937.3%
Equity (SPY)14.9%18.0%0.7031.2%
Gold (GLD)10.9%16.6%0.533.6%
Commodities (DBC)7.2%18.2%0.3112.1%
Real Estate (VNQ)5.8%20.7%0.2424.8%
Bitcoin (BTCUSD)57.1%66.3%0.9710.6%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10302026
Short Interest: Shares Quantity1.8 Mil
Short Interest: % Change Since 10152026-25.2%
Average Daily Volume0.5 Mil
Days-to-Cover Short Interest3.4 days
Basic Shares Quantity42.7 Mil
Short % of Basic Shares4.3%

Earnings Returns History

Updated 11/13/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/4/20261.2%-2.1% 
8/5/20260.1%-0.6%-5.1%
5/6/20264.3%1.7%-4.3%
2/25/202613.0%5.3%14.4%
10/29/20259.6%5.3%17.6%
7/30/2025-5.2%2.4%2.6%
4/30/20250.8%-1.9%6.5%
2/26/2025-10.8%-13.7%-13.1%
...
SUMMARY STATS   
# Positive181113
# Negative61310
Median Positive2.4%5.3%10.5%
Median Negative-6.2%-2.5%-5.9%
Max Positive14.1%15.1%27.0%
Max Negative-13.2%-13.7%-16.6%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/4/20261.2%-2.1% 
8/5/20260.1%-0.6%-5.1%
5/6/20264.3%1.7%-4.3%
2/25/202613.0%5.3%14.4%
10/29/20259.6%5.3%17.6%
7/30/2025-5.2%2.4%2.6%
4/30/20250.8%-1.9%6.5%
2/26/2025-10.8%-13.7%-13.1%
10/30/20242.4%8.5%7.2%
7/31/2024-7.2%-4.6%6.6%
5/1/20248.9%13.6%15.4%
2/21/20242.3%5.9%10.5%
11/1/20230.5%3.4%7.7%
8/2/20230.3%-1.4%-4.9%
5/3/2023-4.5%-8.4%-6.7%
2/22/2023-4.5%-3.6%-16.6%
11/2/202211.1%15.1%20.7%
8/3/20221.7%-2.5%0.8%
5/4/20223.7%-0.3%27.0%
2/24/2022-13.2%-9.2%-7.4%
11/3/20215.7%3.5%-1.5%
8/4/202114.1%13.1%17.8%
5/5/20211.4%-0.5%-10.3%
2/24/20210.8%-3.4%-4.8%
SUMMARY STATS   
# Positive181113
# Negative61310
Median Positive2.4%5.3%10.5%
Median Negative-6.2%-2.5%-5.9%
Max Positive14.1%15.1%27.0%
Max Negative-13.2%-13.7%-16.6%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202611/04/202610-Q
06/30/202608/05/202610-Q
03/31/202605/06/202610-Q
12/31/202502/25/202610-K
09/30/202510/29/202510-Q
06/30/202507/30/202510-Q
03/31/202504/30/202510-Q
12/31/202402/26/202510-K
09/30/202410/30/202410-Q
06/30/202407/31/202410-Q
03/31/202405/01/202410-Q
12/31/202302/21/202410-K
09/30/202311/01/202310-Q
06/30/202308/02/202310-Q
03/31/202305/03/202310-Q
12/31/202202/22/202310-K
Collapse to Preview
Report DateFiling DateFiling
09/30/202611/04/202610-Q
06/30/202608/05/202610-Q
03/31/202605/06/202610-Q
12/31/202502/25/202610-K
09/30/202510/29/202510-Q
06/30/202507/30/202510-Q
03/31/202504/30/202510-Q
12/31/202402/26/202510-K
09/30/202410/30/202410-Q
06/30/202407/31/202410-Q
03/31/202405/01/202410-Q
12/31/202302/21/202410-K
09/30/202311/01/202310-Q
06/30/202308/02/202310-Q
03/31/202305/03/202310-Q
12/31/202202/22/202310-K
09/30/202211/02/202210-Q
06/30/202208/03/202210-Q
03/31/202205/04/202210-Q
12/31/202102/24/202210-K
09/30/202111/03/202110-Q
06/30/202108/04/202110-Q
03/31/202105/05/202110-Q
12/31/202002/24/202110-K
09/30/202010/28/202010-Q
06/30/202007/29/202010-Q
03/31/202004/29/202010-Q
12/31/201902/26/202010-K

Insider Activity

Updated 11/18/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Rothblatt, Martine AChairperson & CEOby TrustSell11182026580.439,5005,514,046188,315,120Form
2Rothblatt, Martine AChairperson & CEOby TrustSell11172026587.749,5005,583,501190,687,138Form
3Rothblatt, Martine AChairperson & CEOby TrustSell11162026592.429,5005,627,991192,206,571Form
4Rothblatt, Martine AChairperson & CEOby TrustSell11132026593.529,5005,638,445192,563,593Form
5Rothblatt, Martine AChairperson & CEOby TrustSell11122026593.999,5005,642,870192,714,688Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Rothblatt, Martine AChairperson & CEOby TrustSell11182026580.439,5005,514,046188,315,120Form
2Rothblatt, Martine AChairperson & CEOby TrustSell11172026587.749,5005,583,501190,687,138Form
3Rothblatt, Martine AChairperson & CEOby TrustSell11162026592.429,5005,627,991192,206,571Form
4Rothblatt, Martine AChairperson & CEOby TrustSell11132026593.529,5005,638,445192,563,593Form
5Rothblatt, Martine AChairperson & CEOby TrustSell11122026593.999,5005,642,870192,714,688Form
6Rothblatt, Martine AChairperson & CEOby TrustSell11122026586.329,5005,570,085190,228,966Form
7Rothblatt, Martine AChairperson & CEOby TrustSell11102026584.591,614943,521189,664,645Form
8Rothblatt, Martine AChairperson & CEOby TrustSell11102026572.697,8864,516,253186,730,389Form
9Patusky, ChristopherDirectSell11102026580.001,210701,8001,241,200Form
10Rothblatt, Martine AChairperson & CEOby TrustSell11092026564.519,5005,362,824183,150,602Form
11Rothblatt, Martine AChairperson & CEOby TrustSell11062026597.761,9601,171,609193,938,876Form
12Rothblatt, Martine AChairperson & CEOby TrustSell11062026573.897,5404,327,122187,319,050Form
13Mahon, Paul AEVP & GENERAL COUNSELDirectSell11052026598.678,3004,968,93327,042,968Form
14Rothblatt, Martine AChairperson & CEOby TrustSell11052026611.061,7231,052,854198,253,689Form
15Rothblatt, Martine AChairperson & CEOby TrustSell11042026599.647,7774,663,396195,581,995Form
16Rothblatt, Martine AChairperson & CEOby TrustSell11042026601.929,5005,718,264195,289,551Form
17Rothblatt, Martine AChairperson & CEOby TrustSell11032026596.229,5005,664,136193,440,974Form
18Rothblatt, Martine AChairperson & CEOby TrustSell11022026600.099,5005,700,856194,695,042Form
19Rothblatt, Martine AChairperson & CEOby TrustSell10302026594.789,5005,650,415192,972,361Form
20Rothblatt, Martine AChairperson & CEOby TrustSell10292026585.499,5005,562,190189,959,329Form
21Rothblatt, Martine AChairperson & CEOby TrustSell10282026587.739,5005,583,418190,684,315Form
22Rothblatt, Martine AChairperson & CEOby TrustSell10272026588.649,5005,592,095190,980,628Form
23Rothblatt, Martine AChairperson & CEOby TrustSell10262026582.769,5005,536,235189,072,916Form
24Rothblatt, Martine AChairperson & CEOby TrustSell10232026583.389,5005,542,094189,273,000Form
25Rothblatt, Martine AChairperson & CEOby TrustSell10222026560.079,5005,320,681181,711,329Form
26Rothblatt, Martine AChairperson & CEOby TrustSell10212026553.879,5005,261,741179,698,412Form
27Rothblatt, Martine AChairperson & CEOby TrustSell10202026543.329,5005,161,576176,277,592Form
28Rothblatt, Martine AChairperson & CEOby TrustSell10192026534.669,5005,079,275173,466,860Form
29Rothblatt, Martine AChairperson & CEOby TrustSell10162026546.659,5005,193,200177,357,610Form
30Mahon, Paul AEVP & GENERAL COUNSELDirectSell10152026544.308,3004,517,70924,587,223Form
31Rothblatt, Martine AChairperson & CEOby TrustSell10152026539.999,5005,129,873175,194,883Form
32Rothblatt, Martine AChairperson & CEOby TrustSell10142026545.529,5005,182,414176,989,264Form
33Rothblatt, Martine AChairperson & CEOby TrustSell10132026550.709,5005,231,666178,671,321Form
34Rothblatt, Martine AChairperson & CEOby TrustSell10132026544.949,5005,176,936176,802,169Form
35Rothblatt, Martine AChairperson & CEOby TrustSell10092026534.319,5005,075,919173,352,246Form
36Rothblatt, Martine AChairperson & CEOby TrustSell10082026548.959,5005,215,015178,102,648Form
37Rothblatt, Martine AChairperson & CEOby TrustSell10072026538.679,5005,117,412174,769,313Form
38Rothblatt, Martine AChairperson & CEOby TrustSell10062026541.649,5005,145,537175,729,840Form
39Rothblatt, Martine AChairperson & CEOby TrustSell10052026549.379,5005,219,015178,239,243Form
40Rothblatt, Martine AChairperson & CEOby TrustSell10022026576.479,5005,476,462187,031,569Form
41Mahon, Paul AEVP & GENERAL COUNSELDirectSell10012026564.958,3004,689,05125,519,734Form
42Rothblatt, Martine AChairperson & CEOby TrustSell10012026550.221,9201,056,425178,515,483Form
43Rothblatt, Martine AChairperson & CEOby TrustSell10012026517.977,5803,926,177169,044,715Form
44Rothblatt, Martine AChairperson & CEOby TrustSell9302026477.429,5004,535,480154,895,232Form
45Rothblatt, Martine AChairperson & CEOby TrustSell9292026480.859,5004,568,106156,009,484Form
46Rothblatt, Martine AChairperson & CEOby TrustSell9282026476.179,5004,523,635154,490,712Form
47Rothblatt, Martine AChairperson & CEOby TrustSell9252026473.559,5004,498,753153,640,926Form
48Rothblatt, Martine AChairperson & CEOby TrustSell9242026491.579,5004,669,918159,486,532Form
49Rothblatt, Martine AChairperson & CEOby TrustSell9232026494.839,5004,700,851160,542,954Form
50Rothblatt, Martine AChairperson & CEOby TrustSell9222026494.559,5004,698,271160,454,848Form
51Rothblatt, Martine AChairperson & CEOby TrustSell9212026494.799,5004,700,505160,531,141Form
52Mahon, Paul AEVP & GENERAL COUNSELDirectSell9182026497.548,3004,129,60822,475,018Form
53Rothblatt, Martine AChairperson & CEOby TrustSell9182026496.069,5004,712,580160,943,552Form
54Rothblatt, Martine AChairperson & CEOby TrustSell9172026501.399,5004,763,172162,671,355Form
55Rothblatt, Martine AChairperson & CEOby TrustSell9162026501.599,5004,765,119162,737,852Form
56Mesa, NildaDirectSell9152026505.87228115,3382,822,742Form
57Rothblatt, Martine AChairperson & CEOby TrustSell9152026504.129,5004,789,152163,558,614Form
58Rothblatt, Martine AChairperson & CEOby TrustSell9142026500.829,5004,757,773162,486,976Form
59Rothblatt, Martine AChairperson & CEOby TrustSell9112026502.359,5004,772,295162,982,923Form
60Rothblatt, Martine AChairperson & CEOby TrustSell9102026501.849,5004,767,467162,818,038Form
61Rothblatt, Martine AChairperson & CEOby TrustSell9092026499.039,5004,740,795161,907,145Form
62Rothblatt, Martine AChairperson & CEOby TrustSell9082026489.209,5004,647,354158,715,959Form
63Rothblatt, Martine AChairperson & CEOby TrustSell9042026487.549,5004,631,619158,178,579Form
64Mahon, Paul AEVP & GENERAL COUNSELDirectSell9032026482.038,3004,000,83621,774,190Form
65Rothblatt, Martine AChairperson & CEOby TrustSell9032026493.469,5004,687,841160,098,663Form
66Rothblatt, Martine AChairperson & CEOby TrustSell9022026514.099,5004,883,839166,792,367Form
67Rothblatt, Martine AChairperson & CEOby TrustSell9012026511.099,5004,855,312165,818,118Form
68Rothblatt, Martine AChairperson & CEOby TrustSell8312026517.519,5004,916,363167,903,124Form
69Rothblatt, Martine AChairperson & CEOby TrustSell8282026522.579,5004,964,376169,542,835Form
70Rothblatt, Martine AChairperson & CEOby TrustSell8272026517.289,5004,914,190167,828,886Form
71Rothblatt, Martine AChairperson & CEOby TrustSell8262026517.719,5004,918,273167,968,348Form
72Rothblatt, Martine AChairperson & CEOby TrustSell8252026511.979,5004,863,730166,105,599Form
73Rothblatt, Martine AChairperson & CEOby TrustSell8242026518.399,5004,924,666168,186,670Form
74Rothblatt, Martine AChairperson & CEOby TrustSell8202026526.969,5005,006,104170,967,928Form
75Rothblatt, Martine AChairperson & CEOby TrustSell8192026515.609,5004,898,221167,283,528Form
76Rothblatt, Martine AChairperson & CEOby TrustSell8182026506.599,5004,812,568164,358,327Form
77Rothblatt, Martine AChairperson & CEOby TrustSell8172026498.919,5004,739,664161,868,516Form
78Rothblatt, Martine AChairperson & CEOby TrustSell8142026504.249,5004,790,316163,598,381Form
79Rothblatt, Martine AChairperson & CEOby TrustSell8132026515.039,5004,892,748167,096,619Form
80Rothblatt, Martine AChairperson & CEOby TrustSell8122026522.879,5004,967,292169,642,433Form
81Rothblatt, Martine AChairperson & CEOby TrustSell8112026530.119,5005,036,073171,991,437Form
82Rothblatt, Martine AChairperson & CEOby TrustSell8102026531.389,5005,048,137172,403,446Form
83Rothblatt, Martine AChairperson & CEOby TrustSell8072026525.369,5004,990,873170,447,784Form
84Mahon, Paul AEVP & GENERAL COUNSELDirectSell8062026517.058,3004,291,51223,356,169Form
85Rothblatt, Martine AChairperson & CEOby TrustSell8062026518.749,5004,927,985168,300,027Form
86Rothblatt, Martine AChairperson & CEOby TrustSell8052026517.099,5004,912,310167,764,697Form
87Rothblatt, Martine AChairperson & CEOby TrustSell8042026516.069,5004,902,569167,432,029Form
88Rothblatt, Martine AChairperson & CEOby TrustSell8032026518.969,5004,930,098168,372,184Form
89Rothblatt, Martine AChairperson & CEOby TrustSell7302026522.379,5004,962,488169,478,360Form
90Rothblatt, Martine AChairperson & CEOby TrustSell7282026526.739,5005,003,976170,895,246Form
91Rothblatt, Martine AChairperson & CEOby TrustSell7272026530.429,5005,038,971172,090,399Form
92Rothblatt, Martine AChairperson & CEOby TrustSell7272026531.749,5005,051,519172,518,929Form
93Rothblatt, Martine AChairperson & CEOby TrustSell7242026528.589,5005,021,520171,494,406Form
94Rothblatt, Martine AChairperson & CEOby TrustSell7232026530.579,5005,040,380172,138,525Form
95Rothblatt, Martine AChairperson & CEOby TrustSell7222026532.249,5005,056,298172,682,164Form
96Rothblatt, Martine AChairperson & CEOby TrustSell7212026531.699,5005,051,035172,502,403Form
97Rothblatt, Martine AChairperson & CEOby TrustSell7202026537.059,5005,101,939174,240,899Form
98Rothblatt, Martine AChairperson & CEOby TrustSell7172026530.919,5005,043,689172,251,528Form
99Mahon, Paul AEVP & GENERAL COUNSELDirectSell7162026533.698,3004,429,63824,107,904Form
100Rothblatt, Martine AChairperson & CEODirectSell7162026530.411,718911,25321,488,701Form
101Rothblatt, Martine AChairperson & CEOby TrustSell7162026530.347,7824,127,087172,064,308Form
102Rothblatt, Martine AChairperson & CEODirectSell7152026526.839,5005,004,90921,343,565Form
103Rothblatt, Martine AChairperson & CEODirectSell7142026535.999,5005,091,94921,714,752Form
104Rothblatt, Martine AChairperson & CEODirectSell7132026544.609,5005,173,66022,063,208Form
105Malcolm, JanDirectSell7102026550.59325178,942247,766Form
106Rothblatt, Martine AChairperson & CEODirectSell7092026551.139,5005,235,75622,328,020Form
107Rothblatt, Martine AChairperson & CEODirectSell7092026553.179,5005,255,11122,410,561Form
108Rothblatt, Martine AChairperson & CEODirectSell7082026558.879,5005,309,29622,641,632Form
109Rothblatt, Martine AChairperson & CEODirectSell7072026548.969,5005,215,13322,240,074Form
110Rothblatt, Martine AChairperson & CEODirectSell7012026541.009,5005,139,54221,917,711Form
111Rothblatt, Martine AChairperson & CEODirectSell6302026545.809,5005,185,13322,112,136Form
112Rothblatt, Martine AChairperson & CEODirectSell6292026543.979,5005,167,73422,037,939Form
113Rothblatt, Martine AChairperson & CEODirectSell6262026550.409,5005,228,77322,298,238Form
114Rothblatt, Martine AChairperson & CEODirectSell6252026548.699,5005,212,52022,228,928Form
115Edgemond, JamesCFO AND TREASURERDirectSell6232026538.158,7504,708,78610,158,061Form
116Rothblatt, Martine AChairperson & CEODirectSell6232026537.749,5005,108,52721,785,448Form
117Edgemond, JamesCFO AND TREASURERDirectSell6222026540.1510,0005,401,48810,195,850Form
118Rothblatt, Martine AChairperson & CEODirectSell6222026540.189,5005,131,71121,884,316Form
119Rothblatt, Martine AChairperson & CEODirectSell6172026549.809,5005,223,06822,273,913Form
120Rothblatt, Martine AChairperson & CEODirectSell6162026549.159,5005,216,91822,247,683Form
121Edgemond, JamesCFO AND TREASURERDirectSell6162026549.1710,0005,491,74210,366,212Form
122Rothblatt, Martine AChairperson & CEODirectSell6152026541.399,5005,143,21421,933,372Form
123Edgemond, JamesCFO AND TREASURERDirectSell6122026549.2910,0005,492,89410,368,386Form
124Rothblatt, Martine AChairperson & CEODirectSell6122026549.239,5005,217,68422,250,953Form
125Rothblatt, Martine AChairperson & CEODirectSell6112026545.839,5005,185,36522,113,126Form
126Rothblatt, Martine AChairperson & CEODirectSell6102026549.329,5005,218,53422,254,575Form
127Edgemond, JamesCFO AND TREASURERDirectSell6092026547.5010,0005,475,04510,334,695Form
128Rothblatt, Martine AChairperson & CEODirectSell6092026547.499,5005,201,11022,180,269Form
129Rothblatt, Martine AChairperson & CEODirectSell6082026547.629,5005,202,43622,185,927Form
130Edgemond, JamesCFO AND TREASURERDirectSell6052026546.2810,0005,462,82410,311,627Form
131Rothblatt, Martine AChairperson & CEODirectSell6052026546.339,5005,190,12822,133,435Form
132Mahon, Paul AEVP & GENERAL COUNSELDirectSell6042026547.078,3004,540,64224,712,036Form
133Rothblatt, Martine AChairperson & CEODirectSell6042026547.619,5005,202,27122,185,221Form
134Rothblatt, Martine AChairperson & CEODirectSell6032026538.399,5005,114,74221,811,950Form
135Rothblatt, Martine AChairperson & CEODirectSell6022026547.919,5005,205,10522,197,306Form
136Edgemond, JamesCFO AND TREASURERDirectSell6022026547.8710,0005,478,66310,341,525Form
137Rothblatt, Martine AChairperson & CEODirectSell6012026553.839,5005,261,36522,437,231Form
138Edgemond, JamesCFO AND TREASURERDirectSell5292026565.6310,0005,656,29810,676,829Form
139Rothblatt, Martine AChairperson & CEODirectSell5292026565.649,5005,373,59222,915,826Form
140Rothblatt, Martine AChairperson & CEODirectSell5282026575.409,5005,466,28323,311,109Form
141Rothblatt, Martine AChairperson & CEODirectSell5262026567.749,5005,393,55823,000,971Form
142Edgemond, JamesCFO AND TREASURERDirectSell5222026564.1110,0005,641,13010,648,197Form
143Rothblatt, Martine AChairperson & CEODirectSell5222026564.119,5005,359,01122,853,645Form
144Rothblatt, Martine AChairperson & CEODirectSell5202026567.949,5005,395,39923,008,820Form
145Rothblatt, Martine AChairperson & CEODirectSell5182026568.119,5005,397,07723,015,977Form
146Edgemond, JamesCFO AND TREASURERDirectSell5152026574.4710,0005,744,74610,843,782Form
147Rothblatt, Martine AChairperson & CEODirectSell5152026574.489,5005,457,56623,273,933Form
148Mesa, NildaDirectSell5132026581.93258150,1392,925,969Form
149Rothblatt, Martine AChairperson & CEODirectSell5132026578.389,5005,494,56323,431,708Form
150Rothblatt, Martine AChairperson & CEODirectSell5112026564.959,5005,367,04422,887,899Form
151Edgemond, JamesCFO AND TREASURERDirectSell5112026578.5810,0005,785,77510,921,229Form
152Rothblatt, Martine AChairperson & CEODirectSell5112026578.549,5005,496,08423,438,196Form
153Rothblatt, Martine AChairperson & CEODirectSell5062026576.249,5005,474,24023,345,041Form
154Rothblatt, Martine AChairperson & CEODirectSell5042026570.589,5005,420,47223,115,744Form
155Edgemond, JamesCFO AND TREASURERDirectSell5012026572.6110,0005,726,06210,808,514Form
156Rothblatt, Martine AChairperson & CEODirectSell5012026572.639,5005,439,99123,198,984Form
157Rothblatt, Martine AChairperson & CEODirectSell4302026571.229,5005,426,59823,141,869Form
158Edgemond, JamesCFO AND TREASURERDirectSell4282026568.8310,0005,688,31910,737,271Form
159Rothblatt, Martine AChairperson & CEODirectSell4282026568.819,5005,403,68423,044,154Form
160Rothblatt, Martine AChairperson & CEODirectSell4272026564.819,5005,365,67822,882,074Form
161Patusky, ChristopherDirectSell4242026569.002,9101,655,790847,810Form
162Edgemond, JamesCFO AND TREASURERDirectSell4242026572.219,6365,513,83010,801,065Form
163Rothblatt, Martine AChairperson & CEODirectSell4242026572.359,5005,437,34023,187,677Form
164Edgemond, JamesCFO AND TREASURERDirectSell4242026575.85364209,60810,938,754Form
165Rothblatt, Martine AChairperson & CEODirectSell4222026570.429,5005,419,00623,109,495Form
166Rothblatt, Martine AChairperson & CEODirectSell4202026586.669,5005,573,22323,767,157Form
167Mahon, Paul AEVP & GENERAL COUNSELDirectSell4162026576.828,3004,787,59726,056,062Form
168Rothblatt, Martine AChairperson & CEODirectSell4162026580.369,5005,513,40123,512,042Form
169Rothblatt, Martine AChairperson & CEODirectSell4162026579.369,5005,503,94923,471,736Form
170Rothblatt, Martine AChairperson & CEOby TrustSell4162026536.957540,271174,209,669Form
171Rothblatt, Martine AChairperson & CEODirectSell4132026569.289,5005,408,19423,063,386Form
172Edgemond, JamesCFO AND TREASURERDirectSell4102026577.8910,0005,778,92210,908,292Form
173Rothblatt, Martine AChairperson & CEODirectSell4102026577.889,5005,489,81923,411,479Form
174Rothblatt, Martine AChairperson & CEODirectSell4082026564.019,5005,358,11622,849,826Form
175Edgemond, JamesCFO AND TREASURERDirectSell4062026561.5010,0005,614,98410,598,844Form
176Rothblatt, Martine AChairperson & CEODirectSell4062026561.379,5005,333,05322,742,944Form
177Mahon, Paul AEVP & GENERAL COUNSELDirectSell4022026565.878,3004,696,69025,561,312Form
178Rothblatt, Martine AChairperson & CEODirectSell4022026581.639,5005,525,52623,563,751Form
179Rothblatt, Martine AChairperson & CEODirectSell4022026585.769,5005,564,70923,730,848Form
180Rothblatt, Martine AChairperson & CEODirectSell3312026590.599,5005,610,56423,926,399Form
181Edgemond, JamesCFO AND TREASURERDirectSell3312026593.1710,0005,931,68311,196,645Form
182Causey, ChristopherDirectSell3302026604.641,300786,0322,533,442Form
183Rothblatt, Martine AChairperson & CEODirectSell3302026526.969,5005,006,10021,348,643Form
184Edgemond, JamesCFO AND TREASURERDirectSell3272026535.9010,0005,359,00510,115,658Form
185Rothblatt, Martine AChairperson & CEODirectSell3272026535.819,5005,090,21621,707,360Form
186Rothblatt, Martine AChairperson & CEODirectSell3252026529.369,5005,028,91921,445,958Form
187Rothblatt, Martine AChairperson & CEODirectSell3232026524.999,5004,987,38721,268,842Form
188Rothblatt, Martine AChairperson & CEODirectSell3202026528.839,5005,023,88421,424,487Form
189Rothblatt, Martine AChairperson & CEODirectSell3182026536.759,5005,099,10421,745,262Form
190Malcolm, JanDirectSell3172026533.514524,00866,689Form
191Rothblatt, Martine AChairperson & CEODirectSell3172026533.909,5005,072,01921,629,759Form
192Olian, Judy DDirectSell3162026535.44200107,0882,380,031Form
193Rothblatt, Martine AChairperson & CEODirectSell3162026534.99516276,0534,501,378Form
194Rothblatt, Martine AChairperson & CEODirectSell3162026538.009,5005,110,96769,940Form
195Rothblatt, Martine AChairperson & CEODirectSell3162026537.978,9844,833,09569,936Form
196Rothblatt, Martine AChairperson & CEODirectSell3112026539.549,5005,125,64770,140Form
197Rothblatt, Martine AChairperson & CEODirectSell3112026539.719,5005,127,27370,163Form
198Olian, Judy DDirectSell3092026510.00200102,0002,368,950Form
199Rothblatt, Martine AChairperson & CEODirectSell3092026484.559,5004,603,23262,992Form
200Mahon, Paul AEVP & GENERAL COUNSELDirectSell3052026483.168,3004,010,18717,801,366Form
201Rothblatt, Martine AChairperson & CEODirectSell3052026317.9719,0006,041,41441,336Form
202Kurzweil, RayDirectSell3052026489.024,9102,401,0886,195,883Form
203Thompson, Tommy GDirectSell3052026489.422,000978,8394,150,279Form
204Causey, ChristopherDirectSell3052026490.17209,8032,053,806Form
205Rothblatt, Martine AChairperson & CEODirectSell3052026499.429,5004,744,46764,924Form
206Olian, Judy DDirectSell3022026509.55200101,9102,468,770Form
207Causey, ChristopherDirectSell2252026520.001,000520,0002,178,800Form
208Benkowitz, MichaelPRESIDENT AND COOby TrustSell2242026472.1314,440  Form
209Benkowitz, MichaelPRESIDENT AND COOby TrustSell2182026480.7522,500  Form
210Malcolm, JanDirectSell2172026474.685023,734104,430Form
211Benkowitz, MichaelPRESIDENT AND COOby TrustSell2102026474.6522,500  Form
212Mahon, Paul AEVP & GENERAL COUNSELDirectSell2052026483.258,3004,010,94017,774,262Form
213Malcolm, JanDirectSell2032026474.235023,712128,042Form
214Benkowitz, MichaelPRESIDENT AND COOby TrustSell2032026470.9522,500  Form
215Benkowitz, MichaelPRESIDENT AND COOby TrustSell1282026471.9122,500  Form
216Benkowitz, MichaelPRESIDENT AND COOby TrustSell1282026464.667,875  Form
217Benkowitz, MichaelPRESIDENT AND COOby TrustSell1282026464.6614,625  Form
218Malcolm, JanDirectSell1202026460.985023,049147,514Form
219Benkowitz, MichaelPRESIDENT AND COOby TrustSell1132026479.5122,500  Form
220Benkowitz, MichaelPRESIDENT AND COOby TrustSell1072026487.3814,625  Form
221Benkowitz, MichaelPRESIDENT AND COOby TrustSell1072026487.387,875  Form
222Causey, ChristopherDirectSell1062026510.001,000510,0002,136,900Form
223Malcolm, JanDirectSell1062026495.015024,750183,154Form
224Causey, ChristopherDirectSell1052026500.011,000500,0152,095,061Form
225Mahon, Paul AEVP & GENERAL COUNSELDirectSell1022026485.438,3004,029,07617,854,633Form
226Benkowitz, MichaelPRESIDENT AND COOby TrustSell12302025502.7922,500  Form
227Mahon, Paul AEVP & GENERAL COUNSELDirectSell12292025513.1811,0005,644,95418,875,186Form
228Benkowitz, MichaelPRESIDENT AND COOby TrustSell12292025514.3522,500  Form
229Malcolm, JanDirectSell12232025512.125025,606215,090Form
230Sullivan, Louis Wby TrustSell12232025512.135,950  Form
231Rothblatt, Martine AChairperson & CEODirectSell12192025507.072,0001,014,14365,919Form
232Thompson, Tommy GDirectSell12192025500.59910455,5334,244,968Form
233Rothblatt, Martine AChairperson & CEODirectSell12192025508.874,0002,035,48866,153Form
234Rothblatt, Martine AChairperson & CEODirectSell12192025501.044,0002,004,14765,135Form
235Rothblatt, Martine AChairperson & CEODirectSell12162025493.454,0001,973,82064,149Form
236Edgemond, JamesCFO AND TREASURERDirectSell12162025495.363,5171,742,1934,033,248Form
237Rothblatt, Martine AChairperson & CEODirectSell12162025494.724,0001,978,86964,313Form
238Benkowitz, MichaelPRESIDENT AND COOby TrustSell12162025496.3022,500  Form
239Patusky, ChristopherDirectSell12162025495.951,000495,954738,971Form
240Rothblatt, Martine AChairperson & CEODirectSell12122025490.704,0001,962,78363,790Form
241Malcolm, JanDirectSell12122025482.985024,149227,001Form
242Mahon, Paul AEVP & GENERAL COUNSELDirectSell12122025484.6711,0005,331,31617,826,465Form
243Rothblatt, Martine AChairperson & CEODirectSell12122025483.974,0001,935,87962,916Form
244Rothblatt, Martine AChairperson & CEODirectSell12102025480.054,0001,920,19162,406Form
245Mesa, NildaDirectSell12102025481.6318790,0652,545,897Form
246Rothblatt, Martine AChairperson & CEODirectSell12102025478.304,0001,913,18462,178Form
247Edgemond, JamesCFO AND TREASURERDirectSell12092025478.6021,00010,050,5973,896,760Form
248Benkowitz, MichaelPRESIDENT AND COOby TrustSell12092025478.5822,500  Form
249Rothblatt, Martine AChairperson & CEODirectSell12082025484.234,0001,936,93662,950Form
250Rothblatt, Martine AChairperson & CEODirectSell12082025483.284,0001,933,12062,826Form
251Rothblatt, Martine AChairperson & CEODirectSell12052025480.014,0001,920,04362,401Form
252Rothblatt, Martine AChairperson & CEODirectSell12052025475.274,0001,901,08761,785Form
253Rothblatt, Martine AChairperson & CEODirectSell12022025481.294,0001,925,14362,567Form
254Edgemond, JamesCFO AND TREASURERDirectSell12022025479.9921,00010,079,6963,908,042Form
255Rothblatt, Martine AChairperson & CEODirectSell12022025481.934,0001,927,70362,650Form
256Benkowitz, MichaelPRESIDENT AND COOby TrustSell12022025479.9122,500  Form
257Rothblatt, Martine AChairperson & CEODirectSell12012025487.644,0001,950,55063,393Form
258Rothblatt, Martine AChairperson & CEODirectSell12012025485.054,0001,940,20463,057Form
259Mahon, Paul AEVP & GENERAL COUNSELDirectSell11262025486.0611,0005,346,70117,877,911Form
260Edgemond, JamesCFO AND TREASURERDirectSell11262025473.6421,0009,946,5443,856,417Form
261Benkowitz, MichaelPRESIDENT AND COOby TrustSell11262025473.6622,500  Form
262Rothblatt, Martine AChairperson & CEODirectSell11252025475.334,0001,901,30561,792Form
263Rothblatt, Martine AChairperson & CEODirectSell11252025470.784,0001,883,11461,201Form
264Rothblatt, Martine AChairperson & CEODirectSell11212025474.644,0001,898,55861,703Form
265Rothblatt, Martine AChairperson & CEODirectSell11212025478.384,0001,913,52462,190Form
266Rothblatt, Martine AChairperson & CEODirectSell11202025474.584,0001,898,33661,696Form
267Rothblatt, Martine AChairperson & CEODirectSell11202025472.764,0001,891,03761,459Form
268Benkowitz, MichaelPRESIDENT AND COOby TrustSell11182025470.4322,500  Form
269Edgemond, JamesCFO AND TREASURERDirectSell11182025470.3621,0009,877,5353,818,373Form
270Rothblatt, Martine AChairperson & CEODirectSell11182025467.554,0001,870,19260,781Form
271Rothblatt, Martine AChairperson & CEODirectSell11182025462.944,0001,851,77460,183Form
272Rothblatt, Martine AChairperson & CEODirectSell11132025728.964,0002,915,85994,765Form
273Mahon, Paul AEVP & GENERAL COUNSELDirectSell11132025464.7611,0005,112,33517,094,255Form
274Rothblatt, Martine AChairperson & CEODirectSell11132025460.004,0001,839,99659,800Form
275Rothblatt, Martine AChairperson & CEODirectSell11122025451.824,0001,807,28358,737Form
276Benkowitz, MichaelPRESIDENT AND COOby TrustSell11122025452.0722,500  Form
277Edgemond, JamesCFO AND TREASURERDirectSell11122025452.0721,0009,493,4833,669,909Form
278Rothblatt, Martine AChairperson & CEODirectSell11122025448.394,0001,793,54658,290Form
279Rothblatt, Martine AChairperson & CEODirectSell11072025448.254,0001,793,00858,273Form
280Rothblatt, Martine AChairperson & CEODirectSell11072025448.584,0001,794,30858,315Form
281Rothblatt, Martine AChairperson & CEODirectSell11062025437.984,0001,751,92256,937Form
282Rothblatt, Martine AChairperson & CEODirectSell11062025434.134,0001,736,50156,436Form
283Edgemond, JamesCFO AND TREASURERDirectSell11052025436.0921,0009,157,8213,540,152Form
284Rothblatt, Martine AChairperson & CEODirectSell11042025438.304,0001,753,19456,979Form
285Benkowitz, MichaelPRESIDENT AND COOby TrustSell11042025429.2522,500  Form
286Rothblatt, Martine AChairperson & CEODirectSell11042025450.354,0001,801,39858,545Form

Investor Activity (13F)

Updated Nov 19, 2026
13F holdings as of Mar 31, 2026 (Q1 2026)

Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.

Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Avoro Capital Advisors LLC$1.6 Bil15.4%30Hold13F
Eversept Partners, LP$156.7 Mil10.3%104Hold13F
Nepsis Inc.$25.0 Mil8.4%29Hold13F
First Turn Management, LLC$62.1 Mil6.9%33ADD +64.7%13F
Tri Locum Partners LP$41.7 Mil5.9%17TRIM -41.8%13F
Summit Street Capital Management, LLC$33.7 Mil4.8%31Hold13F
Elmind Capital, LP$8.9 Mil2.5%34ADD +36.4%13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
First Turn Management, LLC$62.1 Mil6.9%33ADD +64.7%13F
Elmind Capital, LP$8.9 Mil2.5%34ADD +36.4%13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Tri Locum Partners LP$41.7 Mil5.9%17TRIM -41.8%13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Avoro Capital Advisors LLC$1.6 Bil15.4%30Hold13F
Eversept Partners, LP$156.7 Mil10.3%104Hold13F
First Turn Management, LLC$62.1 Mil6.9%33ADD +64.7%13F
Tri Locum Partners LP$41.7 Mil5.9%17TRIM -41.8%13F
Summit Street Capital Management, LLC$33.7 Mil4.8%31Hold13F
Nepsis Inc.$25.0 Mil8.4%29Hold13F
Elmind Capital, LP$8.9 Mil2.5%34ADD +36.4%13F
Core Cache Last Updated: 11/18/2026